NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial

The Lancet Oncology
Vanesa GregorcMary O'Brien

Abstract

Malignant pleural mesothelioma is an aggressive cancer with highly vascularised tumours. It has poor prognosis and few treatment options after failure of first-line chemotherapy. NGR-hTNF is a vascular-targeting drug that increases penetration of intratumoral chemotherapy and T-cell infiltration by modifying the tumour microenvironment. In this trial, we aimed to investigate the efficacy and safety of NGR-hTNF in patients with malignant pleural mesothelioma who had progressed during or after a first-line treatment. NGR015 was a randomised, double-blind, placebo-controlled phase 3 trial done in 41 centres in 12 countries. Eligible participants had malignant pleural mesothelioma of any histological subtype (epithelial, sarcomatoid, or mixed), were aged 18 years or older, and had an Eastern Cooperative Oncology Group performance status of 0-2 and radiologically documented progressive disease after one pemetrexed-based chemotherapy regimen. Participants were randomly assigned to receive weekly NGR-hTNF 0·8 μg/m2 intravenously plus best investigator choice (n=200), or placebo plus best investigator choice (n=200). Best investigator choice was decided before random assignment and could be single-agent gemcitabine (1000-1250 mg/m2 int...Continue Reading

Citations

Jun 22, 2019·Cancer Immunology, Immunotherapy : CII·Zuzana StrizovaDaniel Smrz
Oct 10, 2019·Expert Review of Respiratory Medicine·Giovanni Luca Ceresoli, Antonio Rossi
Sep 4, 2020·International Journal of Molecular Sciences·Nishant S KulkarniVivek Gupta
Sep 25, 2019·International Journal of Molecular Sciences·Barbara ValentinisCatia Traversari
Mar 11, 2020·Frontiers in Oncology·Cornedine J de GooijerPaul Baas
Mar 7, 2020·Frontiers in Oncology·Anna K NowakGérard Zalcman
Jul 20, 2019·Blood·Lakshmi Nayak, Tracy T Batchelor
Oct 1, 2020·Experimental Dermatology·Carsten WeishauptKarin Loser
Jul 17, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dean A FennellGraham M Wheeler
Nov 8, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Kate RosenEmerson Y Chen
Nov 27, 2020·Therapeutic Advances in Medical Oncology·Haitang YangRen-Wang Peng
Feb 6, 2020·Journal of Medicinal Chemistry·Chiara BorsariMaria P Costi
Feb 23, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y MetaxasUNKNOWN Swiss Group for Clinical Cancer Research (SAKK)
May 19, 2021·Human Vaccines & Immunotherapeutics·Giulio MetroFausto Roila
Jun 3, 2021·Cancers·Fabrizio MarcucciAndrés J M Ferreri
Jun 3, 2021·Journal of Clinical Medicine·Emanuele VitaEmilio Bria
Aug 3, 2021·Trends in Pharmacological Sciences·Yi-Shen ZhuJiayi Lv
Aug 17, 2021·Cancer Treatment Reviews·Wanyuan Cui, Sanjay Popat

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.